Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adriamycin versus liposomal doxorubicin as neoadjuvant chemotherapy for osteosarcoma
ChiCTR1800016574Phase 4Recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Jul 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doxorubicin and pegylated liposomal doxorubicin in osteosarcoma (OS) (2 arms), sponsored by Beijing Jishuitan Hospital. Primary endpoint: Tumor necrosis rate. Started Jul 2018; status: recruiting.
02
Drugs
doxorubicinpegylated liposomal doxorubicin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR1800016574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016574.